This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ekberg, M. Search for Related Content Social Bookmarking                   What's this?

Seven Risks Emerging From Life Patents and Corporate Science

Central Queensland University, Australia

This article examines some of the controversial issues emerging from the privatization of biomedical research and commercialization of biotechnology. The aim is to identify the dominant social, political, and ethical risks associated with the recent shift from academic to corporate science and from the increasing emphasis on investing in research projects that will result in the award of a monopoly patent. Identifying these risks may ultimately assist policy makers in designing new policies or reforming existing practices that will come closer to achieving an equitable balance between science pursued for the advance of knowledge and science pursued for patents and profit. The discussion may also assist the research directors or managers of biopharmaceutical companies in designing corporate policies that will optimize the balance between the serendipity of scientific discovery and the discipline of strategic business planning.

Key Words: life patents • corporate science • biotechnology

Bulletin of Science, Technology & Society, Vol. 25, No. 6, 475-483 (2005)
DOI: 10.1177/0270467605282244


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?